Skip to Content

Pharmalive.Com Releases Annual Top 500 Prescription Medicines Special Report Analyzing Product Performance & Company Strategy

NEWTOWN, Pa., August 2, 2010 – Canon Data Products Group and announce the release of the annual “Top 500 Prescription Medicines” Special Report. This compilation provides professionals working in or serving the pharmaceutical and biotechnology industries with a review of prescription product sales from 2007 through 2009.

Overall U.S. pharmaceutical sales continue to grow, however some of the top-selling prescription medicines are set to lose patent protection during 2010 and 2011. Manufacturers and marketers of these products are taking advantage of their remaining patented months by continuing to penetrate emerging regions and marketing products’ additional indications.

Lipitor, the world’s top-selling prescription drug from 2001 through 2009, produced global sales of $12.54 billion last year. The cholesterol reducer lost its U.S. basic product patent in March 2010 and the patent specifically covering its enantiomeric form is set to expire during June 2011.

Abbott Laboratories’ prize biologic product, Humira, generated a 21.4% increase in sales for the year. Including Eisai’s sales in Japan, Humira produced a total of $5.56 billion in sales. In early 2010, Humira became the first biologic approved in Japan for the treatment of plaque psoriasis and psoriatic arthritis. Abbott executives expect Humira’s strong growth to continue as penetration rates in key therapeutic areas remain low, particularly outside the United States. Humira is expected to become the No. 1 product in 2012 with sales of $8.28 billion, and will retain its top spot until 2016 when sales could exceed $10 billion.

“The leaderboard is shifting as biologics are climbing the global sales ladder while some top blockbuster therapeutic drugs are losing patent protection,” says Andrew Humphreys, editor in chief of Canon Data Products Group. “The industry is in for some very interesting years, due in part to the biopharmaceutical corporate strategy being implemented by many traditional pharma powerhouses.”

This PharmaLive Special Report provides a comprehensive review of the top-selling prescription medicines. Report data includes easy-to-read charts containing:
• 2009 sales rank for each product
• 2009 worldwide sales for each product
• 2008 worldwide sales for each product
• 2007 worldwide sales for each product
• Primary disease/medical use & therapeutic category
• Company name
• First approval date and/or launch date

This PharmaLive Special Report is available at

For more information, contact Sandra Baker at 215-944-9836 or

About Canon Data Products Group
Canon Data Products Group, a division of Canon Communications LLC, publishes PharmaLive and Appliance Special Reports, which provide financial, company, and product statistical data and qualitative analysis for the global pharmaceutical, biotechnology, medical device, and appliance industries; maintains eKnowledgeBase, a comprehensive market intelligence tool serving the pharmaceutical, biotechnology, and medical-device sectors; and manages company-wide Site Licenses for, Med Ad News, and R&D Directions.

Posted: August 2010